91 related articles for article (PubMed ID: 8599821)
1. [What do we know about the significance of vitamin D in Paget's disease of the bone?].
Wilczek H; Stĕpán J; Justová V
Cas Lek Cesk; 1995 Dec; 134(24):785-7. PubMed ID: 8599821
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D in Paget's disease of bone.
Foldes J; Shamir S; Kidroni G; Menczel J
Clin Orthop Relat Res; 1989 Jun; (243):275-9. PubMed ID: 2498022
[TBL] [Abstract][Full Text] [Related]
3. Alterations in vitamin D metabolites during treatment of Paget's disease of bone with calcitonin or etidronate.
Devlin RD; Gutteridge DH; Prince RL; Retallack RW; Worth GK
J Bone Miner Res; 1990 Nov; 5(11):1121-6. PubMed ID: 2125401
[TBL] [Abstract][Full Text] [Related]
4. [The correlation between the serum levels of osteocalcin and 24,25-dihydroxyvitamin D in Paget's disease of bone].
Castro Errecarborde N; de la Piedra Gordo C; Rapado Errazti A
An Med Interna; 1990 Jun; 7(6):286-90. PubMed ID: 2102732
[TBL] [Abstract][Full Text] [Related]
5. Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.
Torres R; de la Piedra C; Rapado A
Scand J Clin Lab Invest; 1989 May; 49(3):279-85. PubMed ID: 2787049
[TBL] [Abstract][Full Text] [Related]
6. [Monitoring plasma levels of vitamin D metabolites in simvastatin (Zocor) therapy in patients with familial hypercholesterolemia].
Wilczek H; Sobra J; Ceska R; Justová V; Jůzová Z; Procházková R; Kvasilová M
Cas Lek Cesk; 1994 Dec; 133(23):727-9. PubMed ID: 7834670
[TBL] [Abstract][Full Text] [Related]
7. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
8. Abnormal vitamin D metabolism in Paget's disease of bone.
Guillard-Cumming DF; Beard DJ; Douglas DL; Johnson SK; Lawson-Matthew PJ; Russell RG; Kanis JA
Clin Endocrinol (Oxf); 1985 Apr; 22(4):559-66. PubMed ID: 3872746
[TBL] [Abstract][Full Text] [Related]
9. Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment.
Papapoulos SE; Frolich M; Mudde AH; Harinck HI; vd Berg H; Bijvoet OL
J Clin Endocrinol Metab; 1987 Jul; 65(1):89-94. PubMed ID: 3495547
[TBL] [Abstract][Full Text] [Related]
10. [The value of the calcitonin test in Paget's disease of bone].
D'Amore M; Bozzi A; Telesca ML; Carrozzo M
Minerva Med; 1981 Apr; 72(14):865-8. PubMed ID: 7219796
[TBL] [Abstract][Full Text] [Related]
11. [Is beta 2-microglobulin a marker of bone remodeling in Paget's disease of bone?].
Wilczek H
Cas Lek Cesk; 1997 Dec; 136(23):730-2. PubMed ID: 9476376
[TBL] [Abstract][Full Text] [Related]
12. [Decrease of the coefficient of intestinal calcium absorption with normal blood levels of 1,25-dihydroxyvitamin D and decreasing levels of 24,25-dihydroxyvitamin D in Paget's disease of bone].
Traba ML; Climent P; Rapado A; de la Piedra C; Díaz Curiel M
Rev Clin Esp; 1986 Nov; 179(8):401-3. PubMed ID: 3494277
[No Abstract] [Full Text] [Related]
13. Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation.
Mangham DC; Davie MW; Grimer RJ
Bone; 2009 Mar; 44(3):431-6. PubMed ID: 19064007
[TBL] [Abstract][Full Text] [Related]
14. [Importance of vitamin D in prostatic carcinoma].
Wilczek H; Vachalovský
Cas Lek Cesk; 1996 Nov; 135(22):716-8. PubMed ID: 8998822
[TBL] [Abstract][Full Text] [Related]
15. Serum osteocalcin concentrations in Paget's disease of bone.
Wilkinson MR; Wagstaffe C; Delbridge L; Wiseman J; Posen S
Arch Intern Med; 1986 Feb; 146(2):268-71. PubMed ID: 3484940
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor, oestrogen receptor-alpha and calcium-sensing receptor genotypes, bone mineral density and biochemical markers in Paget's disease of bone.
Donáth J; Speer G; Poór G; Gergely P; Tabák A; Lakatos P
Rheumatology (Oxford); 2004 Jun; 43(6):692-5. PubMed ID: 14997007
[TBL] [Abstract][Full Text] [Related]
17. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate.
Constantin A; Laroche M; Moulinier L; Bon E; Ramonjisoa M; Cantagrel A; Mazieres B
Rev Rhum Engl Ed; 1995; 62(7-8):493-500. PubMed ID: 8574612
[TBL] [Abstract][Full Text] [Related]
18. [Paget's disease of the bones: diagnosis and treatment].
Jacobs JW; Huisman AM; van Paassen HC; Bijlsma JW
Ned Tijdschr Geneeskd; 1999 Apr; 143(14):719-25. PubMed ID: 10347626
[TBL] [Abstract][Full Text] [Related]
19. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
20. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
Chakravarty K; Merry P; Scott DG
J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
